Kidney transplant recipients (KTRs) are patients who have received a kidney transplant as a form of kidney replacement therapy for end-stage kidney disease. The management of KTRs requires lifelong multidisciplinary care involving immunosuppressive therapy, regular monitoring of kidney graft function, prevention and treatment of complications, and management of comorbid conditions.

The main goals of post-transplant care are to maintain long-term kidney graft survival, prevent acute and chronic rejection, minimize medication toxicity, detect infections early, and improve patient survival and quality of life.

Enhanced investigation and timely treatment are essential because transplant recipients have increased risks of surgical complications, infections, cardiovascular disease, malignancy, and complications related to immunosuppressive medications.

Epidemiology

Kidney transplantation is the preferred kidney replacement therapy for suitable patients with end-stage kidney disease because it provides improved survival and quality of life compared with long-term dialysis.

The number of kidney transplant recipients continues to increase globally due to advances in transplant surgery, donor availability, and improved immunosuppressive therapies. However, long-term graft survival remains dependent on adherence to medication, regular monitoring, and early management of complications.

Goals of transplant recipient management

The objectives of care include:

• Prevention of acute and chronic graft rejection.

• Maintenance of adequate kidney graft function.

• Prevention and treatment of infections.

• Monitoring and minimizing immunosuppressive drug toxicity.

• Management of cardiovascular and metabolic complications.

• Early detection of malignancy.

• Supporting medication adherence and patient education.

Immunosuppressive therapy

Immunosuppressive treatment consists of:

1. Induction therapy immediately around transplantation to prevent early acute rejection.

2. Maintenance immunosuppression to maintain long-term graft survival.

The choice of therapy depends on:

• Immunological risk.

• Recipient characteristics.

• Donor characteristics.

• Previous rejection episodes.

• Medication toxicity.

Induction therapy

Induction therapy uses antibodies that reduce immune activation during the early post-transplant period.

There are two main groups:

• Interleukin-2 receptor blockers.

• Lymphocyte-depleting agents.

Patients with high immunological risk for acute graft rejection should receive lymphocyte-depleting agents rather than IL-2 receptor antagonists.

Factors associated with high immunological risk

Factors favoring lymphocyte-depleting induction therapy include:

• One or more human leukocyte antigen (HLA) mismatches.

• Younger recipient age with older donor age.

• Panel reactive antibody (PRA) greater than 0%.

• Presence of donor-specific antibodies (DSA).

• Blood group incompatibility.

• Delayed graft function.

• Cold ischemia time greater than 24 hours.

Low-risk patients

Adults

Basiliximab:

• 20 mg intravenously within 2 hours before transplantation.

• Repeat 20 mg intravenously on day 4.

High-risk patients

Rabbit anti-thymocyte globulin:

• 1.5 mg/kg/day intravenously for 4–7 days.

• First dose administered before transplantation during surgery.

Children

For children weighing more than 35 kg:

• Use adult dosing.

For children weighing less than 35 kg:

Basiliximab:

• 10 mg intravenously within 2 hours before transplantation.

• Repeat 10 mg intravenously on day 4.

High-risk children:

Horse anti-thymocyte globulin:

• 1.5 mg/kg/day for 4–7 days.

• First dose administered before transplantation.

Maintenance immunosuppression

Maintenance therapy usually consists of a combination of:

• Calcineurin inhibitor (CNI).

• Antiproliferative medication.

• Corticosteroids when indicated.

Except when mammalian target of rapamycin inhibitors (mTOR inhibitors) are used, immunosuppression should generally begin before or during transplantation without waiting for graft function to establish.

Routine monitoring investigations

Regular monitoring is essential because some immunosuppressive medications have narrow therapeutic windows and may cause toxicity, including nephrotoxicity.

Monthly monitoring includes:

• Serum creatinine.

• Blood urea nitrogen.

• Urinalysis.

• Urine protein assessment.

• Tacrolimus trough level (12-hour level) or cyclosporine level according to treatment regimen.

Pharmacological treatment

Calcineurin inhibitors

Tacrolimus:

• Initial dose: 0.1–0.2 mg/kg/day orally in two divided doses.

• Dose adjusted according to target serum concentration.

If tacrolimus is unavailable:

Cyclosporine (modified):

• 7–12 mg/kg/day orally in two divided doses.

• Adjust according to serum drug levels.

mTOR inhibitors

In selected patients, including some low-risk transplant recipients or patients with specific indications such as Kaposi sarcoma:

Sirolimus:

• Loading dose: 15 mg orally on day 1.

• Maintenance dose: 5 mg/day.

• Target trough concentration: 5–7 ng/mL.

Antiproliferative agents

Mycophenolate mofetil:

• 1–1.5 g orally every 12 hours.

OR

Mycophenolate sodium:

• 360–1080 mg orally every 12 hours.

OR

Azathioprine:

Initial:

• 2–5 mg/kg orally or intravenously after transplantation.

Maintenance:

• 1–3 mg/kg orally once daily.

Corticosteroid therapy

Initial therapy

Methylprednisolone:

• 7 mg/kg intravenously intraoperatively.

• Maximum dose 500 mg.

OR

Prednisolone:

• 1 mg/kg/day orally (maximum 80 mg/day) for the first 3 days after transplantation.

Maintenance therapy

Prednisolone:

• 20 mg/day for 7 days.

• Reduce by 5 mg weekly.

• Maintain approximately 5 mg/day after stabilization.

After four months following transplantation, reduction of immunosuppression may be considered if there has been no acute rejection.

Corticosteroids and calcineurin inhibitors should not be stopped abruptly.

Important considerations

• Non-dihydropyridine calcium channel blockers may be used in some patients to reduce required calcineurin inhibitor doses.

• Medication adherence assessment is essential.

• Education of transplant recipients and family members improves long-term outcomes.

Monitoring schedule for kidney transplant recipients

Kidney transplant recipients require frequent follow-up because of increased risk of:

• Surgical complications during the first three months.

• Opportunistic infections during the first six months.

• Drug-related complications including diabetes mellitus, hypertension, and nephrotoxicity.

Routine monitoring

Differential diagnosis of declining kidney graft function

A reduction in graft function should prompt evaluation for:

1. Acute rejection

   • Immune-mediated injury causing deterioration of kidney function.

2. Calcineurin inhibitor nephrotoxicity

   • Toxic effect from tacrolimus or cyclosporine.

3. Acute kidney injury due to dehydration

   • Reduced kidney perfusion from inadequate fluid status.

4. Urinary tract obstruction

   • Mechanical blockage affecting urine drainage.

5. Kidney graft infection

   • Pyelonephritis or systemic infection affecting graft function.

6. Recurrent kidney disease

   • Return of the original kidney disease in the transplanted kidney.

7. Chronic allograft dysfunction

   • Progressive long-term graft injury.

Complications

Complications after kidney transplantation include:

• Acute rejection.

• Chronic graft dysfunction.

• Opportunistic infections.

• Drug toxicity.

• Hypertension.

• Diabetes mellitus after transplantation.

• Cardiovascular disease.

• Malignancies.

• Bone mineral disorders.

Prevention of complications

Preventive strategies include:

• Strict adherence to immunosuppressive medications.

• Regular transplant clinic attendance.

• Infection prevention and vaccination.

• Blood pressure control.

• Diabetes screening.

• Avoidance of nephrotoxic drugs.

• Patient and family education.